ライフサイエンスコーパス: gene delivery

1 as a broadly used vector system for in vivo gene delivery.

2 more efficiently than adeno-associated viral gene delivery.

3 study the application of NPs to therapeutic gene delivery.

4 espan of the Npc1-/- mice after systemic AAV gene delivery.

5 are several practical barriers to successful gene delivery.

6 te a hydrodynamic effect as the mechanism of gene delivery.

7 using adeno-associated virus (AAV)-mediated gene delivery.

8 acy and safety were evaluated 2 months after gene delivery.

9 gy is to use organic nanoparticles (NPs) for gene delivery.

10 y terminate AT in atria light-sensitized via gene delivery.

11 nal design of nonviral vectors for efficient gene delivery.

12 ted channelrhodopsin-2 (ChR2) expression via gene delivery.

13 th nucleic acids to form lipoplexes used for gene delivery.

14 peutic efficacy was evaluated 2 months after gene delivery.

15 luronic acid (LPH) nanoparticle for systemic gene delivery.

16 s associated with using nonviral vectors for gene delivery.

17 ine if they increased adeno-associated virus gene delivery.

18 tudied as a promising tool for intracellular gene delivery.

19 eat significance in order to achieve optimal gene delivery.

20 t may become a novel nonviral nanosystem for gene delivery.

21 rge number of mice following therapeutic AAV gene delivery.

22 s for developing new approaches for targeted gene delivery.

23 to the trans-Golgi network is necessary for gene delivery.

24 be tuned for improved localized intratumoral gene delivery.

25 nslational block" occurring after Ad.5-mda-7 gene delivery.

26 of the most efficient non-viral systems for gene delivery.

27 present a promising alternative approach for gene delivery.

28 molecular weight PEI (1.8 kDa) for efficient gene delivery.

29 ne of the most critical steps for successful gene delivery.

30 sponsive SELPs for localized matrix-mediated gene delivery.

31 Dawley rats by using lentiviral vector-based gene delivery.

32 he LPDS-nanoplexes showed a greatly improved gene delivery.

33 rapy of metastatic cancer after MSC-mediated gene delivery.

34 ock when used in combination with adenoviral gene delivery.

35 ng biosensing, in vivo imaging, and drug and gene delivery.

36 s posttreatment compared to traditional rAAV gene delivery.

37 t have led to exciting advances in non-viral gene delivery.

38 NPs, and shed light on the NP-based drug and gene delivery.

39 tors for determining HCC incidence after AAV gene delivery.

40 other applications, are used as vehicles for gene delivery.

41 t atrial ejection fraction at 2 months after gene delivery (-4.3 +/- 3.1% vs. 7.5 +/- 3.1%; p = 0.02)

42 We developed a novel method for efficient gene delivery across the central nervous system in neona

43 ility of the AAV9 vector to mediate systemic gene delivery after intravenous administration to perina

44 Intrathecal gene delivery after the onset of peripheral neuropathy o

45 nalized magnetic nanoparticle (MNP)-mediated gene delivery also resulted in sustained gene expression

46 dic technologies are promising platforms for gene delivery and a useful tool for investigating membra

47 ogenesis and should help efforts to engineer gene delivery and anticancer vectors based on the curren

48 n with FUS-BBB opening can provide effective gene delivery and expression in the CNS, demonstrating t

49 mple protocol to achieve substantial, global gene delivery and expression isolated to the cardiac all

50 tors represent an alternative technology for gene delivery and expression with a potential to overcom

51 systems represent the bottom-up approach to gene delivery and gene silencing, in which scientists ar

52 ors are useful experimental tools for stable gene delivery and have been used to treat human inherite

53 Improvements in gene delivery and in preventing immune reactions will be

54 culoviral vectors are inactivated elsewhere, gene delivery and in vivo genome editing via MNP-BVs are

55 elivery system for receptor-mediated drug or gene delivery and novel therapy for rheumatoid arthritis

56 ases, but they are better known as tools for gene delivery and oncolytic anticancer therapy.

57 paradigms in combination with viral-mediated gene delivery and pharmacology.

58 te that these conditions result in efficient gene delivery and prolonged gene expression (up to 21day

59 gene therapy vector because of its efficient gene delivery and relatively mild immunogenicity.

60 Using pooled gene delivery and subtractive gene elimination, we ident

61 dical applications such as targeted drug and gene delivery and theranostics.

62 emic nature and challenges including in vivo gene delivery and transient gene expression.

63 We identified several kinases that influence gene delivery and/or expression by performing a kinome-l

64 hy (CT) and magnetic resonance (MR) imaging, gene-delivery and photothermal therapy.

65 Using chemogenetics, viral-mediated gene delivery, and a specific ion channel agonist, we st

66 YSNs including biosensing, bioimaging, drug/gene delivery, and cancer therapy are discussed in detai

67 These include small molecules, gene delivery, and cell therapy.

68 in the brain, autophagy in the retina, viral gene delivery, and chemical diffusion through the placen

69 ied macrophages, which accomplished targeted gene delivery, and significant expression of reporter an

70 eno-associated viral vectors for therapeutic gene delivery applicable to the treatment of diverse dis

71 s) from clade E are often used as vectors in gene delivery applications.

72 s represent a new and promising nonviral DNA/gene delivery approach endowing immunomodulatory propert

73 We explored a gene delivery approach for JNCL by generating two self-c

74 s the efficacy of non-viral TUS-based hSef-b gene delivery approach for the treatment of prostate can

75 roporation as a safe and effective non-viral gene delivery approach needed in many biological researc

76 We used an in vivo local gene delivery approach to alter CaM function by directly

77 We explored a gene delivery approach using two self-complementary aden

78 SIRT1 levels in MJD mouse model, through the gene delivery approach, significantly ameliorates neurop

79 ctroporation serves as a promising non-viral gene delivery approach, while its current configuration

80 ), Mef2c (M), and Tbx5 (T) using the current gene delivery approach.

81 n the PFC (postsynaptic site), using a viral gene-delivery approach, rescued the otherwise absent pot

82 ess invasive as compared with other physical gene delivery approaches (e.g., electroporation).

83 gene transfer vectors and transient nonviral gene delivery approaches that are prevalent in ongoing c

84 hancer/promoter selection, and the timing of gene delivery are all critical factors for determining H

85 FUS and intravenous neurotrophic (protein or gene) delivery attenuates the damage to the nigrostriata

86 he baculoviral vector was chosen for in vivo gene delivery because of its large loading capacity and

87 ical applications ranging from targeted drug/gene delivery, bio-isolation, detoxification, to nanosur

88 hotodynamic therapy, radiation therapy, drug/gene delivery, biosensing, and bioimaging.

89 er reporter to not only facilitate effective gene delivery but also enable diagnostic monitoring of p

90 r clinical trials, which currently use viral gene delivery, but focus primarily on new advancements i

91 iated viruses (AAVs) are frequently used for gene delivery, but targeting expression to specific cell

92 lide)-b-poly(ethylene glycol) (PLGA-PEG) for gene delivery by a robust self-assembly method.

93 vehicle screening was demonstrated using GFP gene delivery by different formulations of nanopolymers.

94 Recent advances demonstrate whole-brain gene delivery by retro-orbital injection of virus, but s

95 s suggest a set of new design principles for gene delivery by the synergistic co-assembly of mRNA wit

96 oups of drugs enhance adeno-associated virus gene delivery by unknown mechanisms.

97 e that single-dose intravascular Follistatin gene delivery can ameliorate the diabetic progression an

98 Ultrasound-mediated gene delivery can be accomplished within 10 min.

99 anufacturing combined with scaffold-mediated gene delivery can be used to tissue engineer large anato

100 strates that a single intrathecal lentiviral gene delivery can lead to Schwann cell-specific expressi

101 gered release, intracellular drug targeting, gene delivery, cancer stem cell therapy, magnetic drug t

102 s been intensely exploited for drug release, gene delivery, cancer thermotherapy, and energy harvesti

103 reprogramming and crucial steps involved in gene delivery, cell adhesion and culturing conditions th

104 sed, including nanopatterning, targeted drug/gene delivery, cell manipulation, and precision nanosurg

105 to biomedical applications, such as nonviral gene delivery, cell targeting and imaging, anticancer, a

106 eno-associated virus (AAV)-mediated antibody gene delivery could be an alternative to immunisation to

107 The annual market value for successful gene delivery could exceed US$30 billion, and this will

108 Our results have demonstrated that bpoz-2 gene delivery could have prospect in the amelioration of

109 ing for disease diagnosis, targeted drug and gene delivery, directed stem cell differentiation, accel

110 ble their broad applications in the field of gene delivery, drug delivery, bio-imaging, tissue engine

111 owed excellent cellular biocompatibility and gene delivery efficacy using the green fluorescent prote

112 study the effect of polymer architecture on gene delivery efficiency and cell cytotoxicity, a set of

113 resveratrol trimer caraphenol A enhances LV gene delivery efficiency to human and nonhuman primate h

114 Next, rAAV-mediated miR-208a gene delivery enhanced heart contractility and relaxatio

115 We discuss options for gene delivery experiments to test circuit and behavioral

116 Thus, subsequent gene delivery experiments to the explanted porcine heart

117 ents in optimizing the efficacy of non-viral gene delivery for ocular diseases.

118 s (AAV) vectors are the leading platform for gene delivery for the treatment of a variety of human di

119 tential to achieve non-invasive and targeted gene delivery for treatment of CNS diseases.

120 and cartilage tissue engineering, including gene delivery, gene editing, and subpopulation isolation

121 oaches to reducing the costs associated with gene delivery have been developed using microfluidic dev

122 Challenges with gene delivery have limited attempts to treat CF using in

123 ies have found these vesicles are capable of gene delivery, however the consequences of vesicle-media

124 NGF) gene therapy in AD, the first effort at gene delivery in an adult neurodegenerative disorder.

125 bly of ICG, as well as simultaneous targeted gene delivery in an experimental mouse model of cancer.

126 re, conduct and optimize ultrasound-mediated gene delivery in both a murine and a porcine animal mode

127 some-mimics (EMs) in sufficient quantity for gene delivery in cancer both in vitro and in vivo.

128 cations, is used as an expression vector for gene delivery in mammalian cells.

129 cytes, adeno-associated virus (AAV)-mediated gene delivery in mice, and human tissue samples were use

130 ted hepatocellular carcinoma (HCC) after AAV gene delivery in mice.

131 ently being advocated for increasing drug or gene delivery in neurological diseases.

132 nfirms that AAV9 can safely mediate systemic gene delivery in small and large animal models and suppo

133 the key to engineering optimal polymers for gene delivery in the future.

134 c or adeno-associated virus-mediated TNFAIP3 gene delivery in the liver in both mouse and nonhuman pr

135 ransduction method for robust and widespread gene delivery in the mouse brain.

136 deletion and adeno-associated virus-mediated gene delivery in the mouse were used to study calcineuri

137 A (followed by electroporation to facilitate gene delivery) in atria of healthy dogs followed by rapi

138 e, we report that an intravenous Follistatin gene delivery intervention with tropism for striated mus

139 of generated pulses and apply the system for gene delivery into bacterial Dh5alpha cells.

140 us infection as well as be used as tools for gene delivery into epithelial tissues or epithelial tumo

141 Gene delivery into hCD34+ hematopoietic stem/progenitor

142 s paper, we investigated the effect of VPS35 gene delivery into the central nervous system on the dev

143 Gene delivery is enhanced by the action of targeting and

144 The importance of AAVR for in vivo gene delivery is further highlighted by the robust resis

145 These studies demonstrate that non-viral gene delivery is impacted by proteoglycan interactions a

146 The beneficial effect of Klotho gene delivery is likely due to attenuation of T-cell inf

147 One limitation of AAV gene delivery is preexisting neutralizing antibodies, wh

148 mpared to WT and more importantly that TIPE2 gene delivery may provide as a novel anti-inflammatory t

149 of this new method will aid investigation of gene delivery mechanisms by providing the means to rapid

150 We will also highlight the in vivo gene delivery mediated by non-viral vectors to treat can

151 on in mouse pyramidal neurons using in utero gene delivery methodologies.

152 plete treatment and intrinsic variability of gene delivery methods may contribute to the variable out

153 ction is a gentle alternative to established gene delivery methods, and uniquely suited for nonpertur

154 In gene delivery, non-viral vectors have become the preferr

155 Thus, localized ocular gene delivery of AAV-HLA-G1/5 may reduce the off-target

156 Lastly, lung-targeting gene delivery of adenosine or ATPgammaS downstream effec

157 nrichment in liver tumors after hydrodynamic gene delivery of AKT plasmids.

158 Viral-mediated gene delivery of an activating Gq-DREADD to vmPFC and/or

159 Gene delivery of Ang-(1-9) reduced sudden cardiac death

160 ria can be successfully light-sensitized via gene delivery of ChR2.

161 o Adeno-associated virus serotype 9-mediated gene delivery of GJA1-20k to the heart protects Cx43 loc

162 electively immobilize adenoviral vectors for gene delivery of growth factors.

163 after adeno-associated virus (AAV)-mediated gene delivery of mutant human PKP2, which encodes the de

164 Cardiac gene delivery of parvalbumin (Parv), an EF-hand Ca(2+) b

165 sion in mice cardiomyocytes by using in vivo gene delivery of specific short hairpin RNAs.

166 Local gene delivery of the l-DOPA synthesizing enzymes, tyrosi

167 We also show that viral gene delivery of Yap5SA in the postnatal inner ear senso

168 However, their use in gene delivery often exhibits low transfection efficiency

169 escence/nmr), imaging combined with drug and gene delivery, or imaging combined with therapy or diagn

170 Beyond their use in drug/gene delivery, phototherapy, and bioimaging, recent stud

171 ardiomyocyte-specific Pkm2 modified RNA as a gene delivery platform.

172 Understanding the successes and failures of gene delivery polymers and structures is the key to engi

173 rexpression of the Nrg4 gene by hydrodynamic gene delivery prevents HFD-induced weight gain and fatty

174 the development of more efficient AAV-based gene delivery procedures.

175 The application of nanoparticles for drug or gene delivery promises benefits in the form of single-ce

176 Follistatin gene delivery promoted insulinemia and abundance of insu

177 present a polymeric NP system with sustained gene delivery properties, which can be synthesized using

178 study, we successfully established a robust gene delivery protocol for Blastocystis subtype 7 (ST7)

179 do not regenerate and current stem cell and gene delivery protocols result only in immature HC-like

180 ved indicates that the efficiency of cardiac gene delivery remains a major hurdle preventing success

181 putamenal and combined putamenal and nigral gene delivery, respectively.

182 at many genetically-based diseases, however, gene delivery safety and efficacy remains a challenging

183 Ultrasound-mediated gene delivery (sonoporation) is a minimally invasive, no

184 models and clinical trials; however, current gene delivery strategies are limited to the introduction

185 Current gene delivery strategies routinely use cDNA-based vector

186 Transcript length (relevant to gene delivery strategies) correlated significantly with

187 Despite these advantages, gene-delivery strategies using nonviral vectors have poo

188 e vector engineering efforts toward improved gene delivery success with respect to specific tissue ta

189 ansposon system is a highly active non-viral gene delivery system capable of integrating defined DNA

190 utility of the adeno-associated virus (AAV) gene delivery system has been validated by the regulator

191 The adeno-associated virus (AAV) vector gene delivery system has shown promise in several clinic

192 This synergistic gene delivery system provides a viable method for highly

193 The design of a non-viral gene delivery system that can release a functional nucle

194 We expect this NP-mediated gene delivery system to provide safe and sustained relea

195 transduction efficacy of a lentivirus based gene delivery system was not augmented.

196 seases, is currently hampered by the lack of gene delivery systems able to cross the blood-brain barr

197 herapy, and allow for the development of new gene delivery systems based on in vitro-generated papill

198 Therapeutic delivery of drug and gene delivery systems have to traverse multiple biologic

199 Synthetic nanoparticle-based gene delivery systems offer highly tunable platforms for

200 Self-assembled synthetic gene delivery systems represent the bottom-up approach t

201 ry and balance function is likely to require gene delivery systems that target auditory and vestibula

202 ans-splicing system is adaptable to multiple gene delivery systems, and it presents new opportunities

203 execution of inhaled gene therapy, including gene delivery systems, primary physiological barriers an

204 discuss the recent discoveries on non-viral gene delivery systems.

205 a new transfection multiplier for non-viral gene delivery systems.

206 systemically delivered nanoparticle nonviral gene delivery systems.

207 use lungs, superior to several gold standard gene delivery systems.

208 examine the effectiveness of novel non-viral gene delivery systems.

209 avenues towards improving the transition of gene-delivery technologies from in vitro assessment to h

210 However, improvements in gene delivery technology mean that gene therapy has the

211 MCM-based transfection is an advancement in gene delivery technology, as it represents a non-viral a

212 Instead of viral-mediated therapeutic gene delivery, the authors induced expression of an inte

213 ot noted genotoxicity following AAV-mediated gene delivery; therefore, the possibility that there is

214 -ZN-NIMs and their potential to improve oral gene delivery through improved protection and controlled

215 animals is highly effective for AAV-mediated gene delivery throughout the spinal cord and supraspinal

216 he envelope pseudotype while scAAV9 mediates gene delivery to 40% of spinal cord motor neurons, with

217 Our results support the potential for gene delivery to BCs and gene replacement therapy in hum

218 The approach developed here permits targeted gene delivery to blood vessels and could be used to prom

219 Therapeutic gene delivery to hematopoietic stem cells (HSCs) holds g

220 id, has been shown to be highly efficient in gene delivery to human airway epithelia.

221 lish the feasibility of AAV-mediated in vivo gene delivery to immune cells which will facilitate both

222 ctors are incapable of efficient or specific gene delivery to NSCs in vivo.

223 almost exclusively employ viral vectors for gene delivery to NSCs though safety and scalability pose

224 cy, it still remains challenging for precise gene delivery to overcome nonspecific adsorption and off

225 g in cocaine seeking, we used viral-mediated gene delivery to overexpress ADAR2b in the accumbens she

226 Gene delivery to primary human cells is a technology of

227 In conclusion, AAV1 vectors are suitable for gene delivery to TG sensory neurons following intraderma

228 sound is therefore a viable way of enhancing gene delivery to the brain and merits further research.

229 s a noninvasive modality for MR image-guided gene delivery to the brain, it has been used exclusively

230 ighly promising delivery system for systemic gene delivery to the brain.

231 rventions in human cells, including targeted gene delivery to the CCR5 and AAVS1 loci.

232 of persistent transgene expression following gene delivery to the CNS and the first human results whe

233 retofore precluded investigation of systemic gene delivery to the cochlea.

234 1 MPa) 1.1-MHz FUS facilitates sonoselective gene delivery to the endothelium without MRI-detectable

235 ued Kir7.1 channel function after lentiviral gene delivery to the hiPSC-RPE cells.

236 Nonviral gene delivery to the liver has been under evolution for

237 AAV has emerged as the vector of choice for gene delivery to the retina, with attention focused on d

238 ng could be modulated in skeletal muscle via gene delivery to the target tissue, thereby avoiding the

239 ted adeno-associated virus (AAV) vectors for gene delivery to the TG after intradermal whiskerpad del

240 dy provide an important advance in improving gene delivery to treat patients with muscular dystrophy.

241 tion AAVP particles enable improved targeted gene delivery to tumor cells.

242 Reintroduction of HSD17B3 via gene-delivery to Sertoli cells in adulthood partially re

243 Exo-AAV2 serves as a robust gene delivery tool for murine retina, and the simplicity

244 as led to their widespread implementation as gene delivery tools and optical probes.

245 decade, AAV vectors have emerged as leading gene delivery tools for therapeutic applications and bio

246 ent lentiviral vectors (IDLVs) are promising gene delivery tools that retain the high transduction ef

247 n essential option in the array of available gene delivery tools.

248 the QD fluorescence is combined with drug or gene delivery towards theranostic approaches or with com

249 Unfortunately, current methods of gene delivery treat only a fraction of diseased cells, y

250 Gene delivery using a lentiviral vector leads to efficie

251 Gene delivery using vector or viral-based methods is oft

252 us serotype 5 (AAV5) is being developed as a gene delivery vector for several diseases, including hem

253 The ideal gene delivery vector must be non-toxic, non-immunogenic,

254 Taken together, we present an EOC gene delivery vector platform based on AAV with decrease

255 ese results suggest that AAVrh10 is a useful gene delivery vector to target the sensory nerves innerv

256 otably, this biodegradable end-modified PBAE gene delivery vector was not cytotoxic and maintained th

257 y(ethylenimine) (PEI) 25 kDa is an efficient gene delivery vector with outstanding gene condensation

258 unological stealth over the traditional AAV2 gene delivery vector.

259 ated viruses (AAV) are promising therapeutic gene delivery vectors and better understanding of their

260 Viral and non-viral gene delivery vectors are in development for human gene

261 Unfortunately, most gene delivery vectors are incapable of efficient or spec

262 Gene delivery vectors based on adeno-associated virus (A

263 ly poly(ethylene imine) (PEI), are promising gene delivery vectors due to their inherent ability to c

264 pment of peptide vaccines, and generation of gene delivery vectors for cystic fibrosis given the stri

265 ome has implications for the use of SAdVs as gene delivery vectors in human gene therapy and vaccines

266 The synthetic component of hybrid gene delivery vectors plays a significant role in their

267 eno-associated viruses (rAAVs) are efficient gene delivery vectors via intravenous delivery; however,

268 (PAEs) have emerged as a promising class of gene delivery vectors with performances that can even be

269 viruses (AAVs), which are being developed as gene delivery vectors, display differential cell surface

270 The inadequacy of gene delivery vectors, including poor intracellular deli

271 n addition to enhancing MNP functionality as gene delivery vectors, minicircle technology provides ke

272 rther development of this promising class of gene delivery vectors, we have investigated their mechan

273 y for the development of optimized non-viral gene delivery vectors.

274 pecially appealing class of biomaterials for gene delivery vehicles as they can be introduced into th

275 ntly considered the safest and most reliable gene delivery vehicles for human gene therapy.

276 Viral vectors, in particular, are powerful gene delivery vehicles for the nervous system, but all a

277 Despite their promise as gene delivery vehicles, a better understanding of the bi

278 ) are increasingly becoming attractive human gene delivery vehicles, especially after the approval of

279 When coupled with our previously reported gene delivery vehicles, the slightly cationic microbubbl

280 y parameter for the design of more efficient gene delivery vehicles.

281 to ensure their compatibility with existing gene delivery vehicles.

282 es in bionanotechnology, as drug-delivery or gene-delivery vehicles, as nanoreactors or as templates

283 Controllable gene delivery via vector-based systems remains a formida

284 In particular, the enhancement of gene delivery was approximately 50 to 100 times better w

285 n or adeno-associated virus serotype-9-based gene delivery was capable of strengthening ER function,

286 The gene delivery was cell-type specific with majority of th

287 Global gene delivery was demonstrated in dystrophic mice more t

288 in vivo model, the safety of the adenoviral gene delivery was evaluated.

289 Moreover, GalphasXL gene delivery was found to be capable of inducing hypert

290 Adeno-associated virus (AAV) vector-mediated gene delivery was recently approved for the treatment of

291 Adenoviral gene delivery was shown to be safe, with no detrimental

292 gnal; however, it confirmed that rAAV.sFLT-1 gene delivery was well tolerated among the elderly.

293 By viral gene delivery, we downregulated mTORC2 solely in the dor

294 sults suggest that adenovirus-mediated ABCC6 gene delivery, when initiated early, is a promising prev

295 WT hAIPL1 by adeno-associated virus-mediated gene delivery, which was stable up to 6 months after tre

296 that silica cloaking of Ad can enhance viral gene delivery while reducing immunogenicity.

297 the score on the CHOP INTEND scale followed gene delivery, with an increase of 9.8 points at 1 month

298 re promising vectors for in vivo therapeutic gene delivery, with more than 20 years of intense resear

299 rotrophic factors (either through protein or gene delivery) without FUS, ameliorates the damage to th

300 se of Raman chemical imaging in the field of gene delivery yields unprecedented insight into the unpa